Overview

Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Midazolam